Expressions of plasma D-dimer, von Willebrand factor antigen and blood coagulation factor Ⅶ in lymphoma and their clinical significances
10.3760/cma.j.issn.1009-9921.2019.11.003
- VernacularTitle: 血浆D-二聚体、血管性血友病因子抗原和凝血因子Ⅶ在淋巴瘤中的表达及其临床意义
- Author:
Xiaoyan LIN
1
;
Lili LIU
1
;
Jianfeng ZHOU
1
;
Jiangning ZHAO
2
Author Information
1. Department of Clinical Laboratory, Zhongshan Hospital, Xiamen University, Xiamen 361004, China
2. Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen 361004, China
- Publication Type:Journal Article
- Keywords:
Lymphoma;
D-dimer;
von Willebrand factor antigen;
Blood coagulation factor Ⅶ
- From:
Journal of Leukemia & Lymphoma
2019;28(11):653-657
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical value of blood coagulation and fibrinolysis index detection in lymphoma patients.
Methods:A total of 115 lymphoma patients hospitalized at Zhongshan Hospital of Xiamen University from January 2013 to September 2017 were retrospectively analyzed. According to the diagnostic and therapeutic criteria of lymphoma from World Health Organization (2008), these patients were divided into chemotherapy remission group (76 cases) and chemotherapy non-remission group (39 cases). A total of 138 healthy examination subjects at the same period were selected as the control group. Coagulation factor Ⅶ (FⅦ), D-dimer (D-D), von Willebrand factor antigen (vWF: Ag) and serum lactate dehydrogenase (LDH) levels were measured in all subjects. Kruskal-Wallis test was used to compare the differences of blood coagulation and fibrinolysis indicators in patients with different lymphoma staging and stratified treatment outcomes. Correlation test of D-D and LDH and disease staging was performed by using Spearman correlation analysis. The receiver operating characteristics (ROC) curve was used to analyze the efficacy of D-D in the assisted diagnosis of lymphoma with thrombosis.
Results:The plasma D-D, vWF: Ag levels and FⅦ activity [the median (interquartile range)] in lymphoma patients were higher than those in healthy controls [1 240 ng/ml (1 610 ng/ml) vs. 250 ng/ml (43 ng/ml), Z = -10.728, P < 0.01; 170 ng/ml (113 ng/ml) vs. 105 ng/ml (28 ng/ml), Z = -6.425, P < 0.01; 120% (26%) vs. 96% (26%), Z = -4.602, P < 0.01]. With the increase of Ann Arbor stage, plasma D-D, vWF: Ag levels and FⅦ activity were also increased gradually (all P < 0.05); plasma D-D, vWF: Ag levels and FⅦ activity in lymphoma with thrombosis group were higher than those in the group without thrombosis (all P < 0.01), D-D and vWF: Ag levels in the chemotherapy remission group were lower than those in the chemotherapy non-remission group (all P < 0.01). Plasma D-D levels were positively correlated with LDH level and Ann Arbor stage (r values were 0.414 and 0.530, respectively, all P < 0.01). When the plasma D-D level was 1 735 ng/ml, the sensitivity of diagnosis of thrombosis in patients with lymphoma was 81.8%, the specificity was 85.7%, the area under the ROC curve was 0.894, and the Youden index was the highest (0.675).
Conclusions:Clinically, blood coagulation and fibrinolysis in patients with lymphoma can be evaluated by detecting blood coagulation and fibrinolysis indexes such as plasma D-D. Real-time monitoring of plasma D-D level can determine the thrombosis trend of lymphoma patients, and it may play an important role in evaluating the efficacy and prognosis.
